China Biotechnology Services Holdings Limited was established as a Sino-foreign joint venture in China in 1996 and was listed on the gem of the Hong Kong Stock Exchange in June 2004 under the stock code 8037.HK, referred to as "China Biotechnology Services". The company was included in the Hong Kong MSCI Micro-share Index in May 2018.
Future biotechnology platform
The layout of "accurate diagnosis: accurate Great Health Inspection system" and "accurate treatment: Car-T Integrated Industry chain" ▎ based on Guangdong-Hong Kong-Macau Greater Bay Area facing China and Europe and the United States
Seize the historical opportunity of global precision medical development and strive to become a future biotechnology platform
Cover various human states of health, sub-health and disease, through the combination of individual life numbers and big data's life cycle table, recognize and control customer health throughout the life cycle, and formulate targeted intervention measures. make the disease knowable, controllable and treatable.
CEO： Xiaolin Liu
Listing Date： 06/17/2004